ESR1 and breast carcinoma: In order to assess the relationship of AGR2 with other tumour variables including ERα and with patients' survival, we have examined the immunohistochemical expression of AGR2 in specimens of 351 primary breast carcinomas taken from patients who received no chemotherapy, but the vast majority (93%) of whom were given some form of endocrine treatment, usually tamoxifen post operatively (Table 1).